Why are pharma operating models being forced to evolve?
The pharmaceutical industry is undergoing a significant transformation, driven by a combination of factors including digital adoption, regulatory shifts, telemedicine, and real-time data demands. As a result, pharma organisations are being forced to re-examine their operating models, structuring teams and decision-making processes to meet the changing needs of the industry. In this blog post, we will explore the key drivers of this evolution and the essential elements that pharma companies must incorporate into their operating models to remain competitive.
One of the primary drivers of change in the pharma industry is the increasing adoption of digital technologies. The use of digital tools and platforms is transforming the way pharma companies interact with patients, healthcare professionals, and other stakeholders. For example, telemedicine is becoming increasingly popular, allowing patients to remotely consult with healthcare professionals and receive medical advice. This shift towards digital engagement is not only improving patient outcomes but also generating vast amounts of data that can be used to inform business decisions.
However, the increasing use of digital technologies also presents significant challenges for pharma companies. The sheer volume and complexity of data being generated require modern infrastructure and advanced analytics capabilities to process and interpret. Moreover, the use of digital tools and platforms raises important questions about data privacy and security, which must be addressed through robust compliance frameworks.
Regulatory shifts are another key driver of change in the pharma industry. Governments and regulatory agencies are imposing increasingly stringent requirements on pharma companies, particularly with regards to data privacy, security, and transparency. For example, the European Union’s General Data Protection Regulation (GDPR) and the United States’ Health Insurance Portability and Accountability Act (HIPAA) impose significant obligations on pharma companies to protect patient data and ensure compliance with regulatory requirements.
In response to these regulatory shifts, pharma companies must develop operating models that prioritise compliance and risk management. This requires cross-functional collaboration between different departments, including legal, regulatory, and compliance teams, to ensure that all aspects of the business are aligned with regulatory requirements. Moreover, pharma companies must invest in modern infrastructure and technology to support compliance and risk management, such as data analytics and reporting tools.
The increasing demand for real-time data is also driving change in the pharma industry. Patients, healthcare professionals, and other stakeholders expect pharma companies to provide timely and accurate information about products, services, and treatments. To meet this demand, pharma companies must develop operating models that support faster feedback loops and more agile decision-making processes.
This requires a fundamental shift in the way pharma companies structure their teams and decision-making processes. Traditional hierarchical structures and linear decision-making processes are no longer sufficient in an industry where speed and responsiveness are essential. Instead, pharma companies must adopt more agile and flexible operating models, characterised by cross-functional collaboration, empowered teams, and data-driven decision-making.
So, what are the essential elements of a pharma operating model that is fit for purpose in this rapidly changing industry? First and foremost, pharma companies must prioritise cross-functional collaboration and teamwork. This requires breaking down silos and fostering a culture of collaboration and communication across different departments and functions.
Second, pharma companies must invest in modern infrastructure and technology to support digital adoption, regulatory compliance, and real-time data demands. This includes investing in cloud-based platforms, data analytics tools, and other digital technologies that can help to drive business outcomes and improve patient engagement.
Third, pharma companies must develop faster feedback loops and more agile decision-making processes. This requires adopting more flexible and adaptive operating models, characterised by empowered teams, data-driven decision-making, and a culture of continuous learning and improvement.
Finally, pharma companies must prioritise compliance and risk management, ensuring that all aspects of the business are aligned with regulatory requirements and that risks are identified and mitigated. This requires investing in compliance frameworks, risk management tools, and other technologies that can help to support regulatory compliance and risk management.
In conclusion, the pharma industry is undergoing a significant transformation, driven by digital adoption, regulatory shifts, telemedicine, and real-time data demands. To remain competitive, pharma companies must develop operating models that prioritise cross-functional collaboration, modern infrastructure, faster feedback loops, and compliance and risk management. By adopting these essential elements, pharma companies can ensure that they are well-positioned to meet the changing needs of the industry and deliver better outcomes for patients and other stakeholders.
News Source: https://www.growthjockey.com/blogs/operating-model-changes-pharma-industry
About the Author
